On January 31st, Novo Nordisk released its 2023 results, with a total annual revenue of DKK 232.261 billion (approximately USD 33.771 billion), a year-on-year increase of 31%; The operating profit was DKK 102.574 billion (approximately USD 14.914 billion), a year-on-year increase of 37%.
By region, the regional revenue in the United States was DKK 127.534 billion (approximately USD 18.543 billion), a year-on-year increase of 51%. The regional revenue in China was 16.687 billion Danish kroner (approximately 2.426 billion US dollars), a year-on-year increase of 3%. Among them, GLP-1 product revenue was 6.208 billion Danish kroner (approximately 903 million US dollars), accounting for 76.6% of the market share in China.
As a star product of Novo Nordisk, Smegglutide achieved sales of 145.811 billion Danish kroner (approximately 21.201 billion US dollars) in 2023. Among them, Smeaglutide injection Ozempic (type 2 diabetes) earned DKK 95.718 billion (about USD 13.917 billion), up 60% year on year; The revenue of Rybelsus (type 2 diabetes), a Smeaglutide tablet, was 18.75 billion Danish kroner (about 2.726 billion US dollars), up 66% year on year; Wegovy (Obesity) received 31.343 billion Danish kroner (approximately 4.557 billion US dollars) in revenue from Smegglutide Injection, a year-on-year increase of 407%.
In addition, the board of directors of Novo Nordisk has decided to launch a stock buyback program with a total amount of up to 20 billion Danish kroner (approximately 2.908 billion US dollars).